Rapport Therapeutics announced that its Phase 2a trial of RAP-219 in refractory focal epilepsy is now fully enrolled. This milestone positions the company to report topline results in September 2025, a key catalyst for its lead program. The trial utilizes intracranial electroencephalography (iEEG) data from the RNS System to assess RAP-219’s effect on long episodes (LEs), an objective biomarker correlated with clinical seizures.
The company also provided an update on its Phase 1 development, presenting final aggregate safety data from three completed multiple dose trials, including the PET trial. These data, involving 64 healthy volunteers, continue to reinforce RAP-219’s differentiated tolerability profile.
Financially, Rapport reported $285.4 million in cash, cash equivalents, and short-term investments as of March 31, 2025. These funds are projected to support the company's operations through the end of 2026, providing a stable financial runway as it approaches critical clinical readouts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.